Is Catabasis Pharmaceuticals (CATB) A Good Stock To Buy Now?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Posts Tagged ‘NASDAQ:CATB’
Hedge Funds Have Never Been This Bullish On Catabasis Pharmaceuticals Inc (CATB)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Is Catabasis Pharmaceuticals Inc (CATB) A Good Stock To Buy?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
31 Stories To Find Out How Is It Going In The Financial Markets Today
"The Nasdaq crossed the 6,000 threshold for the first time on Tuesday, while the Dow registered triple-digit gains as strong earnings underscored the health of Corporate America...
Catabasis Pharmaceuticals Inc (CATB): What’s Next?
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) is the latest biotechnology company to fall foul of some disappointing data in the space.
Here’s Why These Five Stocks Are in the Spotlight Today
In this article, we will analyze five stocks that are showing considerable more movement than the broader market and are attracting more interest, Bassett Furniture Industries...
What is Going on With These Falling Stocks?
It's profit-taking day as all three major indexes are lower.
What We’re Watching For In The Upcoming Catabasis Pharmaceuticals Inc (CATB) Data
Catabasis Pharmaceuticals Inc (NASDAQ:CATB) is a tiny junior biotech based in Massachusetts, with one lead development candidate of any note (there are a couple of preclinical...
5 Stocks That Are Getting Battered and Bruised Today
At a time when crude futures are in the green and the major indexes are flat, shares of five stocks, Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Flexion Therapeutics Inc (NASDAQ...
Here is What Hedge Funds Think About Catabasis Pharmaceuticals Inc (CATB)
Many investors, including Carl Icahn or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that ...
Camber Capital Quick To Move On This Newly-Listed Biotech Stock
According to a recent filing with the Securities and Exchange Commission, Stephen DuBois's Camber Capital Management initiated a position in the newly-listed clinical-stage biopharmaceutical...
Hedge Fund Resource Center
